Response to COVID-19
Testing is a critical part of addressing the COVID-19 threat. This battle is fought on multiple fronts, from physicians’ offices and urgent care clinics to hospitals and molecular labs, from emergency departments to those hotspots where help is needed most.
We are working across our company and in partnership with others to support communities worldwide with resources and technologies to fight this evolving threat. Aiding in the development of new tests so people can receive the critical results they need, ensuring continued access to critical biological samples for diagnostics development without disruption.
Fast, accurate detection, and monitoring for the health issues that may arise as part of COVID-19 disease management are critical. Our sample availability in immunoassays, chemistry, hematology, hemostasis, molecular, and urinalysis can help support the essential role of laboratory diagnostics. We are continuing to support the in-vitro diagnostics industry by expanding our infectious disease sample collection capabilities to address the COVID-19 pandemic.
New York Biologics can provide PCR transport media, as well as serology samples (positives and negatives), with date of symptom onset.
The battle is fought on multiple fronts. We are proud to assist the IVD industry in this fight against SARS-CoV-2